Quarterly report pursuant to Section 13 or 15(d)

11. Related Party Transactions (Details Narrative)

v3.20.1
11. Related Party Transactions (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Research and development expense $ 359,651 $ 463,782  
Advanced payment 1,310,314   $ 722,079
Hesperix [Member]      
Repayment of loan     225,000
Pharmsynthez [Member] | Sponsored Research Agreement [Member]      
Research and development expense 100,000    
Payment for research agreement     350,000
Advanced payment 100,000   200,000
Pharmsynthez [Member] | Co-Development Agreement [Member]      
Payment for note receivable     $ 500,000
Note receivable outstanding $ 500,000    
Note receivable interest rate 10.00%    
Interest income $ 13,000